Skip to main content
Download PDF

Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV

Allergy, Asthma & Clinical Immunology volume 19, Article number: 91 (2023) Cite this article

Abstract

Background

There is an urgent need to understand the interplay between SARS-CoV-2 and HIV to inform risk-mitigation approaches for HIV-infected individuals.

Objectives

We conclude that people living with HIV (PLWH) who are antiretroviral therapy (ART) naïve could be at a greater risk of morbidity or mortality once co-infected with SARS-CoV-2.

Methods

Here, we performed extensive immune phenotyping using flow cytometry. Moreover, to compare the range of values observed in the co-infected case, we have included a larger number of mono-infected cases with SARS-CoV-2. We also quantified soluble co-inhibitory/co-stimulatory molecules in the plasma of our patients.

Results

We noted a robust immune activation characterized by the expansion of CD8+ T cells expressing co-inhibitory/stimulatory molecules (e.g. PD-1, TIM-3, 2B4, TIGIT, CD39, and ICOS) and activation markers (CD38, CD71, and HLA-DR) in the co-infected case. We further found that neutrophilia was more pronounced at the expense of lymphopenia in the co-infected case. In particular, naïve and central memory CD8+ T cells were scarce as a result of switching to effector and effector memory in the co-infected case. CD8+ T cell effector functions such as cytokine production (e.g. TNF-α and IFN-γ) and cytolytic molecules expression (granzyme B and perforin) following anti-CD3/CD28 or the Spike peptide pool stimulation were more prominent in the co-infected case versus the mono-infected case. We also observed that SARS-CoV-2 alters T cell exhaustion commonly observed in PLWH.

Conclusion

These findings imply that inadequate immune reconstitution and/or lack of access to ART could dysregulate immune response against SARS-CoV-2 infection, which can result in poor clinical outcomes in PLWH. Our study has implications for prioritizing PLWH in the vaccination program/access to ART in resource-constrained settings.

Background

The outbreak of the Coronavirus Disease 2019 (COVID-19) has led to an unprecedented global challenge. A better understanding of COVID-19 pathogenesis, in particular, in people with underlying health conditions such as human immunodeficiency virus (HIV) is urgently needed. According to the UNAIDS, 38 million people are living with HIV (PLWH) worldwide, however, only 73% of these individuals are on antiretroviral therapy (ART) [1]. Hence, ~ 10 million PLWH who are not on ART may experience CD4+ T cell loss and subsequently compromised adaptive immunity [2]. Because lymphopenia is an indicator of poor clinical outcomes in SARS-CoV-2-infected individuals [3, 4], it is possible to suggest that lymphopenia delays the elimination of SARS-CoV-2, favoring myeloid cell activation and cytokine storm [5,6,7]. Even though ART suppresses viral replication, HIV-infected individuals experience chronic immune activation characterized by increased pro-inflammatory cytokines, dysregulated regulatory T cell effector functions, and T cell exhaustion [8,9,10]. Systemic immune activation is associated with comorbid conditions and accelerated aging in PLWH [11, 12]. This immune dysregulation might increase the risk of mortality and morbidity associated with COVID-19. Several epidemiological studies have investigated the clinical features and prognosis of COVID-19 among PLWH with inconsistent results, likely due to disparities in comorbidities [13, 14]. However, recent studies have indicated that untreated advanced HIV (defined as a low CD4+ T cell count and lack of ART) are associated with more severe clinical outcomes with SARS-CoV-2 infection [15,16,17]. Importantly, lower CD4+ T cell count has been considered a risk factor for severe COVID-19 irrespective of viral suppression in PLWH [18]. Furthermore, PLWH have a higher rate of comorbidities than the general population, which may contribute to the poor clinical outcomes observed following infection with SARS-CoV-2 [17]. For example, older age, male sex, hypertension, and cardiovascular diseases are associated with an increase in the odds of having severe COVID-19 in PLWH [19]. Similarly, older age, male sex, hypertension, diabetes, tuberculosis, kidney disease, and malignancy are linked to an increase in the likelihood of in-hospital mortality in PLWH [19]. Although the use of ART has been associated with improved clinical outcomes, HIV has remained a risk factor for COVID-19 severity/mortality regardless of viral load [19].

Moreover, it is possible to suggest that residual immune perturbation in PLWH may influence the magnitude and quality of the adaptive immune response to SARS-CoV-2 infection. For instance, a more pronounced CD4+ T cell decline or inverted CD4/CD8 ratio is considered a prognostic factor for poor clinical outcomes in PLWH [20]. We and others have reported that CD4+ T cells exhibit a more pronounced immune response against SARS-CoV-2 antigens than CD8+ T cells [20, 21]. Therefore, CD4+ T cell deficiency may influence the humoral immune response as evidenced by a lower IgG conversion rate and a rapid decline in antibody titer in PLWH compared to HIV-uninfected individuals [22].

In addition to antibodies, successful viral clearance requires an effective T cell response [23, 24]. The crucial role of antigen-specific CD8+ T cells or cytotoxic T cells (CTLs) in the elimination of virus-infected cells has been well described [23, 25]. However, in the setting of chronic antigenic stimulation (e.g. HIV, HCV, and cancer) CTLs become gradually dysfunctional or exhausted [26]. CTL exhaustion is characterized by the loss of effector functions but upregulation of multiple co-inhibitory receptors (e.g. PD-1, TIM-3) [26, 27]. Although transient up-regulation of co-inhibitory receptors occurs in acute infections, their persistent upregulation is the hallmark of CTL exhaustion [26, 28]. This is particularly relevant for PLWH, in whom the combined effect of lower CD4+ T cells/exhausted CTLs and residual immune dysregulation could impair the development of immunity against a new pathogen such as SARS-CoV-2 [29]. To date, limited studies have compared immune responses in HIV/SARS-CoV-2 co-infected versus SARS-CoV-2 mono-infected individuals. To address this knowledge gap, we performed immunophenotyping and functional assays on fresh peripheral blood mononuclear cells from a co-infected patient compared to a SARS-CoV-2 mono-infected individual concurrently admitted to the hospital. Moreover, we have compared the co-infected case with a larger number of mono-infected cases with SARS-CoV-2. Our results reveal robust immune activation in the co-infected case as a potential contributing factor to respiratory failure/pulmonary fibrosis and death.

Methods

Study subjects

The diagnosis of COVID-19 infection was performed by RT-PCR specific for viral RNA-dependent RNA polymerase and envelope transcripts (Omicron) using an endotracheal aspirate or nasopharyngeal swab. In addition to our cases, we recruited 64 SARS-CoV-2 infected and ICU-admitted patients for comparison.

Sample collection and processing

Fresh blood samples were processed and subjected to Ficoll-Hypaque gradients for the isolation of peripheral blood mononuclear cells (PBMCs). PBMCs were cultured in RPMI 1640 (Sigma-Aldrich) supplemented with 10% FBS (Sigma-Aldrich) and 1% penicillin/streptomycin (Sigma-Aldrich).

Flow cytometry-based immune phenotyping and functional assays

Fluorophore antibodies with specificity to human cell surface antigens and cytokines were purchased mainly from BD Biosciences or Thermo Fisher Scientific. Specifically, the following antibodies were used: anti-CD3 (HIT3a), anti-CD4 (RPA-T4), anti-CD8 (RPA-T8), anti–TIM-3 (7D3), anti–PD-1 (MIH4), anti-CD244 (DM244), anti-ICOS (C398.A4), anti-TIGIT (MBSA43), anti-CD39 (TU66), anti-CD73 (AD2), anti-CCR7 (2-L1-A), anti-CD45RA (HI100), anti-perforin (δG9), anti–granzyme B (GB11), anti–HLA-DR (LN3), anti-CD38 (HIT2),anti-CD71 (MA712), anti-CD235A (HIR2), anti-CD14 (M5E2), anti-CD16 (B73.1), anti-CD33 (WM-53), anti-CD11b (M1/70), anti–TNF-α (MAB11), and anti–IFN-γ (4S.B3). Freshly isolated PBMCs were subjected to immune phenotyping. Similarly, fresh PBMCs were cultured and stimulated with either anti-CD3/CD28 antibodies or SARS-CoV-2 Spike (S) peptide pools (Miltenyi Biotec), which contained the immunodominant sequence domains of the surface glycoproteins S, in the presence of brefeldin A (10 μg/ml) for 6 h according to our previous protocols [8, 30]. Then cells were fixed with 4% paraformaldehyde and acquired on a Fortessa-X20 or LSR Fortessa-SORP flow cytometer (BD Biosciences) and analyzed with FlowJo software (version 10).

Soluble effector cell checkpoints quantification

We measured soluble levels of checkpoint molecules in the plasma using the U-PLEX effector cell checkpoint combo kit (MSD Meso Scale Diagnostics) [31].

Results

Description of Cases

SARS-CoV-2 and HIV co-infected case

This was a 40-year-old woman who was admitted to hospital for acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 infection (Omicron variant) for 6 days in March 2022. She was discharged but after 4 days returned to hospital with headache, nausea, cough, chest pain, shortness of breath, and progressive respiratory failure requiring intubation. She was admitted to the intensive care unit (ICU) for mechanical ventilation support. She was also supported with vasopressors for shock. She was treated with dexamethasone and empiric antibiotics. The patient had known untreated HIV infection. She was vaccinated against SARS-CoV-2 but it was unclear whether she had received one or two shots of vaccine. Her CD4+ T cell count at the time of admission was 5 cells/mm3 (1%) and her most recent plasma viral load count was 150,000 copies/mL. Her complete blood count (CBC) analysis at the time of admission time and 2 days later is summarized in Table 1.

Table 1 The complete blood count (CBC) of the co-infected case on the admission day and 2 days later
Full size table

In brief, the patient had leukocytosis characterized by a massive expansion of neutrophils and immature granulocytes but lymphopenia. Moreover, she had low red blood cell (RBC), hemoglobin and hematocrit levels and a low mean corpuscular volume (MCV). After readmission to the ICU, which occurred 10 days after the onset of ARDS, a blood sample was drawn for immunological studies.

ART was initiated while in the ICU but despite all the efforts 1 month in ICU, the patient died due to respiratory failure/pulmonary fibrosis and multi-organ failure from COVID-19.

SARS-CoV-2 mono-infected case

This was a 49-year-old male with poorly controlled type 2 diabetes mellitus admitted to the ICU with ARDS due to COVID-19 on the same day as the co-infected case. He presented with cough and fever for a few days, and decreased level of consciousness. This patient had received two doses of vaccine in May and June 2021 but no booster. Upon admission to the ICU, he was treated with dexamethasone. He was supported with mechanical ventilation and tracheostomized. CBC on the day of admission and 2 days later showed leukocytosis, characterized by neutrophilia. He was also noted to have low RBC count, hemoglobin, and hematocrit levels (Table 2). The patient improved, was weaned off the ventilator, transferred out of the ICU after 10 days and eventually released from the hospital.

Table 2 The complete blood count (CBC) of the mono-infected case on the admission day and 2 days later
Full size table

A massive expansion of CD8+ T cells expressing co-inhibitory/stimulatory receptors in the HIV/SARS-CoV-2 co-infected case versus SARS-CoV-2 mono-infected patient

To better understand how HIV/SARS-CoV-2 coinfection influences immune cell phenotype and function, we sought to conduct immunophenotyping on these two cases. The co-infected case had extremely low levels of CD4+ T cells compared to the SARS-CoV-2 mono-infected patient and a healthy control (HC, male 50-year-old) who was not infected with SARS-CoV-2 but vaccinated twice (Fig. 1a). However, CD8+ T cells were enriched in the co-infected case as reported in PLWH [23]. The low frequency of CD4+ T cells in the co-infected case made further immunophenotyping of this T cell subset impractical. As such, we decided to characterize CD8+ T cells in terms of co-inhibitory receptor expression and activation status. Our analysis revealed substantial expansion of CD8+ T cells or cytotoxic T lymphocytes (CTLs) expressing a wide range of co-inhibitory/stimulatory receptors such as TIM-3, 2B4 (CD244), PD-1, ICOS, CD39, and TIGIT in the HIV/SARS-CoV-2 co-infected case compared to the mono-infected case and HC (Fig. 1b). Of note, the frequency of CTLs expressing ICOS, PD-1, CD39, TIM-3, and TIGIT were distinctively higher in the co-infected case than the mono-infected case (Fig. 1b). Moreover, we noted that the proportion of CTLs expressing different co-inhibitory receptors was clearly higher in the co-infected case when compared to 64 ICU-admitted mono-infected individuals with SARS-CoV-2 (Fig. 1c–h). In contrast, CD73 expressing CTLs were diminished in the co-infected case compared to the mono-infected case (Fig. 1b) and the larger ICU-admitted mono-infected cohort (Fig. 1i). Moreover, we quantified the levels of different checkpoint molecules in the plasma of mono- and-co-infected cases. These analyses revealed higher levels of soluble TIM-3, TIGIT, PD-1, OX40, Lag-3, CD28 and CD27 in the plasma of HIV-SARS-CoV-2 co-infected versus the mono-infected case. However, CD40L level was lower in the co-infected versus mono-infected case (Fig. 1j).

Fig. 1
figure 1

Expansion of CD8+ T cells expressing co-inhibitory/stimulatory receptors in the HIV/SARS-CoV-2 co-infected case. a Representative flow cytometry plot of the gating strategy and percentages of CD4+ and CD8+ T cells in the peripheral blood mononuclear cells (PBMCs) of a healthy control (HC), SARS-CoV-2 mono-infected or co-infected (HIV + SARS-CoV-2). b Representative flow cytometry plots of TIM-3/2B4, PD-1/ICOS, CD39/CD73, and TIGIT expressing CTLs of mono-and-co-infected individuals and a HC. c–i Cumulative data of 2B4+, TIM-3+, ICOS+, PD-1+, CD39+, TIGIT+, and CD73+CD8+ T cells in ICU admitted mono-infected patients vs. the co-infected case, respectively. j The plasma levels of different co-inhibitory and co-stimulatory molecules in the mono-and-co-infected cases. k Representative plots, and l cumulative data showing the percentages of naïve, T central memory (TCM), T effector memory (TEM), and effector memory re-expressing CD45RA (TEMRA) CD8+ T cell in the co-infected case vs. the ICU admitted cohort of mono-infected individuals

Full size image

Abundance of highly activated effector and effector memory CTLs in the co-infected case

To gain a deeper understanding of the impact of co-infection on CTL phenotype, we analyzed the percentage of different CTL subsets in the co-infected versus mono-infected individuals. Our results revealed a noticeable decline in the frequency of naïve and T central memory (TCM) CD8+ T cells but an increased proportion of effector memory (TEM) and effector CD8+ T cells expressing CD45RA (TEMRA) (Fig. 1k). This difference was also noticeable when the co-infected individual was compared to the cohort of mono-infected ICU-admitted individuals (Fig. 1l). Moreover, we observed a higher proportion of activated CTLs expressing HLA-DR and CD38 in the co-infected case when compared to the mono-infected case (Fig. 2a) and even to a larger cohort of mono-infected patients with SARS-CoV-2 (Fig. 2b, c). Similarly, we found an increase in the abundance of CD71+CTLs in the co-infected case (Fig. 2d, e). This suggests that CTLs in the co-infected case possess a higher proliferative capacity, considering that CD71 is highly co-expressed with Ki67 in activated T cells [32]. Overall, these observations indicate that CTLs in the co-infected case exhibit a highly-activated phenotype compared to their counterparts in the mono-infected case.

Fig. 2
figure 2

a Enhanced CD8+ T cells activation, increased the frequency of CECs, and alteration in the frequency of different monocyte subpopulations in the co-infected case. a Representative flow cytometry plots, and b cumulative data of percentages of CD38/ and c HLA-DR expression in CD8+ T cells from a HC, mono-and-co-infected individuals. d Representative plots, and e cumulative data of percentages of CD8+CD71+ T cells in the mono-infected compared to the co-infected case and a HC. f Flow cytometry plots showing percentages of CD71+CD235a+ cells in PBMCs from a HC, mono-and-co-infected individuals. g Flow cytometry plots of percentages of monocytes (CD14 +) in PBMCs from a HC, mono-and-co-infected individuals. h Percentages of different monocytes subpopulations (classical, non-classical, and intermediate monocytes) in PBMCs of the mono-infected cohort compared to the co-infected individual and a HC. i Flow cytometry plots of percentages of CD14+HLADR+ monocytes in the mono-infected cohort compared to the co-infected case and a HC. j The gating strategy and representative plots of myeloid-derived suppressor cells (MDSCs) and their subpopulations either monocytic (M-MDSC) or granulocytic (G-MDSC) in PBMCs from a HC, mono-and-co-infected individuals

Full size image

CD71+ erythroid cells (CECs) are abundant in the co-infected case

CECs co-express CD71 and CD235a in humans and considered as erythroid progenitors/precursors [33]. It is reported that CECs are expanded in the peripheral blood of SARS-CoV-2-infected individuals, which is more prominent in infected individuals with the Wuhan strain of SARS-CoV-2 than the Delta and Omicron variants [34, 35]. CECs not only have immunosuppressive properties [36] but also get infected with SARS-CoV-2, which may in part explain the mechanism associated with hypoxia in COVID-19 patients [6]. Therefore, we examined the proportion of CECs in the peripheral blood of the mono- and-co-infected cases. We found that the co-infected case had a very high proportion of CECs compared to the mono-infected case and the HC (Fig. 2f).

Increased frequency of non-classical monocytes but decreased myeloid-derived suppressor cells (MDSCs) in the co-infected case

Immune dysregulation manifested by the expansion of myeloid cells at the expense of lymphopenia is commonly observed in severe COVID-19 [37]. Therefore, we investigated the frequency of monocytes and their subsets including classical (CD14hi CD16−/lo), non-classical (CD14−/lo CD16hi), and intermediate monocytes (CD14hi CD16hi) in the co-infected case compared to the mono-infected individual. The frequency of total monocytes in the co-infected case was 50% lower than the mono-infected individual (Fig. 2g) but the percentage of non-classical monocytes was higher in the co-infected case (Fig. 2h). The proportion of intermediate monocytes remained unchanged in the co-infected case versus the mono-infected case (Fig. 2h). We further characterized monocytes based on the expression of HLA-DR and found that the proportion of HLA-DR expressing monocytes was higher in co-infected versus the mono-infected case (Fig. 2i). Finally, we characterized the frequency of MDSCs in our patients, which revealed a low percentage of MDSCs (4.6%) in the co-infected case compared to the mono-infected individual (25.5%) and HC (24%) (Fig. 2j).

CTLs from the co-infected case exhibit greater cytokine production and cytolytic molecule expression

HIV infection is associated with the chronic upregulation of co-inhibitory receptors, which subsequently results in CTL exhaustion [8, 23, 26]. To determine the effector functions of CTLs, we quantified IFN-γ and TNF-α expression following stimulation with anti-CD3/CD28 and the Spike peptide pools of SARS-CoV-2. We observed that CTLs from the co-infected case had more robust IFN-γ and TNF-α expression compared to the mono-infected case (Fig. 3a–c). Similar observations were made when we measured IFN-γ and TNF-α response to stimulation with the S peptide pool of SARS-CoV-2 (Fig. 3d–f).

Fig. 3
figure 3

Robust cytokine and cytolytic molecules expression in the co-infected versus mono-infected case. a Representative flow cytometry plots, b cumulative data of percentages of TNF-α, and c IFN-γ and expressing CTLs following stimulation with anti-CD3/CD28 from a HC, mono-and-co-infected individuals. Unstimulated control (Unstim). d Representative flow cytometry plots, e cumulative data of percentages of TNF-α, and f IFN-γ and expression in CTLs following stimulation with the S peptide pools from a HC, mono-and-co-infected individuals. g Flow cytometry plots of IFN-γ and TNF-α expression in CD8+PD-1− and CD8+PD-1+ T cells of a HC, mono-and-co-infected individuals following stimulation with anti-CD3/CD28. h Flow cytometry plots of IFN-γ and TNF-α expression in CD8+TIM-3− and CD8+TIM-3+ T cells of a HC, mono-and-co-infected individuals following stimulation with anti-CD3/CD28. i Flow cytometry plots of percentages of perforin and granzyme B (GzmB) expressing cells among CD8.+ T cells of a HC, mono-and-co-infected individuals following stimulation with anti-CD3/CD28

Full size image

Moreover, we investigated the effector functions of CTLs in regard to the expression of PD-1 and TIM-3. Although the expression of PD-1 and TIM-3 is associated with CTL exhaustion in chronic conditions such as HIV and cancer [8, 31, 38], this has not been the case in CTLs from SARS-CoV-2 infected individuals [21]. To better delineate the effector functions of PD-1 + and TIM-3 + CTLs compared to their negative counterparts, we analyzed their cytokine production and cytolytic molecule expression. Interestingly, our results showed that TIM-3 and PD-1expressing CTLs exhibited a greater ability to secrete cytokines compared to their negative siblings (Fig. 3g, h). Of note, CTLs did not show an exhausted phenotype in the co-infected case but rather a highly-activated phenotype. Finally, we found that CTLs from the co-infected case had robust granzyme B (GzmB) and perforin expression compared to the mono-infected case and HC (Fig. 3i).

Discussion and conclusions

Here, we aimed to gain a better understanding of the immune response in an HIV/SARS-CoV-2 co-infected case compared to a SARS-CoV-2 mono-infected individual. Most PLWH who are on ART have an undetectable viral load and reconstituted CD4+ T cell count. It is well documented that SARS-CoV-2 infection is associated with lymphopenia [6]. Therefore, SARS-CoV-2 infection imposes a greater risk of lymphopenia in PLWH, in particular, in those who are ART naïve with a lower CD4+ T cell count. This was evident in our co-infected case with low absolute whole blood lymphocyte count and < 1% CD4+ T cell count in PBMCs. In the absence of ART, uncontrolled viral replication acts as the main driving force for CD4+ T cell depletion and immune dysregulation [12]. This was evidenced by the hyper-immune activation characterized by the expansion of CTLs expressing activation markers (CD38/HLA-DR) and co-stimulatory molecules in the co-infected case. This agrees with another study that has reported significantly higher proportion of activated (CD38/HLA-DR) CD4+ and CD8+ T cells in SARS-CoV-2 co-infected and HIV-unsuppressed compared with HIV suppressed individuals [39]. Moreover, a negative correlation between the frequency of activated (CD38/HLA-DR) CD4+/CD8+ T cells with absolute CD4 counts was noted in co-infected individuals with unsuppressed HIV replication [39]. Upregulation of co-inhibitory receptors (e.g. PD-1 and TIM-3) in T cells of COVID-19 patients has been documented [6, 40]. Most of these reports speculated that T cells expressing co-inhibitory receptors are exhausted without conducting any functional studies [3, 41]. Upregulation of co-inhibitory receptors does not necessarily mean an exhausted T cell phenotype [42] as T cell exhaustion is characterized by functional impairment of T cell effector functions [26]. Notably, transient expression of co-inhibitory receptors on activated T cells is meant to inhibit a robust and deleterious immune response in an acute setting [43]. The massive production and release of inflammatory cytokines and cytolytic molecules (GzmB and perforin) in T cells expressing PD-1 and TIM-3 in the co-infected case compared to their counterparts lacking these co-inhibitory receptors resemble what occurs during T-cell activation [44]. This agrees with our previous report that antigen-specific CD4+ (CD154+) and CD8+ (CD137+) T cells expressing co-inhibitory receptors had significantly higher levels of cytokine (e.g. TNF-α and IFN-γ) production compared to their negative siblings [21]. A similar observation has been reported for antigen-specific PD-1+CD4+ T cells with greater IFN-γ producing capacity, which supports their activated phenotype [20]. Of note, lower IFN-γ production by T cells in acute COVID-19 patients is widely reported [3, 21, 45]. However, our co-infected case exhibited a robust IFN-γ response to both global and antigen-specific stimulation. These observations indicate that SARS-CoV-2 infection alters exhausted CTLs to an activated phenotype in PLWH. This implies that IFN-γ responses were not impaired in the co-infected case despite the anticipated T cell exhaustion due to untreated HIV infection [8, 23, 27]. Therefore, hyper-T cell activation and a reduced proportion of MDSCs may exacerbate the immune response and contribute to cytokine storm commonly observed in COVID-19 patients [5]. The hyperimmune activation is also accompanied by the expansion of non-classical monocytes in PLWH with inflammatory properties [46]. Similarly, expansion of HLA-DR + monocytes supports their robust activation status [5]. The striking observation was the disappearance of neutrophilia 2 days post ICU admission in the SARS-CoV-2 mono-infected case but a robust expansion of neutrophils (from 12.8 to 17.5 × 106/ml blood) in the co-infected case at the same time. It is reported that neutrophilia is more pronounced in COVID-19 patients with severe or critical disease [47, 48]. In line with this, it was found that among COVID-19 patients’ non-survivors had a greater number of neutrophils than survivors [48, 49]. It is worth mentioning that despite a high viral load and low CD4 count, our co-infected case did not exhibit signs of other infections at the time of admission to the ICU.

Of note, CECs are almost absent or in very low frequency in the peripheral blood of healthy individuals [33, 50]. However, their massive expansion in the peripheral blood of acute COVID-19 patients infected with the SARS-CoV-2 (Wuhan strain) has been reported [6, 34]. It is worth mentioning that those infected with the delta and omicron variants display lower frequency of CECs in their circulation [35]. Similarly, a higher proportion of CECs in the peripheral blood of HIV-infected individuals, in particular, the ART-naïve subpopulation has been detected [51]. However, SARS-CoV-2 variants differentially affect erythropoiesis and the Omicron variant is associated with the least expansion of CECs in the peripheral blood of COVID-19 patients [35]. Therefore, a substantial expansion of CECs in the co-infected case versus mono-infected case highlights the synergistic effects of HIV and SARS-CoV-2 on erythropoiesis dysregulation. This was further demonstrated by the lower number of RBCs and anemia in the co-infected case.

Collectively, our results provide insight on the interplay between SARS-CoV-2 and HIV infection. However, there are inconsistencies regarding the influence of SARS-CoV-2 infection on HIV infection. For instance, it has been reported that co-infection of HIV does not increase disease severity by SARS-CoV-2 [52]. This could be explained by performing such studies in societies where every HIV-infected individual has access to ART rather than low resource setting countries. However, emerging results support a greater risk of morbidity and mortality among HIV/SARS-CoV-2 infected individuals, especially in those with uncontrolled viremia and low CD4 + T cell count [53, 54].

However, there are a few study limitations that should be taken into consideration. This is a single case report, which is a major study limitation. Secondly the co-infected case was a female but the mono-infected case was a male. Hence, sex as a biological factor may influence the results [55]. However, we have provided cumulative data to compare the range of values observed in a larger mono-infected cohort versus the co-infected case. Despite these limitations, we still believe our study provides an insight into the interplay between HIV and SARS-CoV-2. Therefore, the subpopulation of PLWH with insufficient immune reconstitution might be more vulnerable to SARS-CoV-2 infection, the development of COVID-19 disease and its associated complications as reported by others [56]. The coexistence of both viruses in those with lower CD4+ T cell count may evolve immune escape mutations leading to adverse public health outcomes. Additionally, unsuppressed HIV replication and hyper immune activation may lead to the depletion of CD4+ T cells and subsequently diminished SARS-CoV-2 antigen-specific T cell response [39]. As such, HIV-associated immune dysregulation in viremic individuals may negatively impact vaccine-induced cellular immunity. Therefore, integration of testing strategies or providing rapid SARS-CoV-2 tests to HIV-infected individuals in low-resource setting countries should be considered.

Availability of data and materials

All data related to this study are incorporated in the text and figures.

References

  1. HIV.gov. Global Statistics. UNAIDS. 2020.

  2. Elahi S, Niki T, Hirashima M, Horton H. Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection. Blood. 2012;119(18):4192–204.

    PubMed  PubMed Central  Google Scholar 

  3. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;130(5):2620–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Chen Z, John WE. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20(9):529–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Bozorgmehr N, Mashhouri S, Perez Rosero E, Xu L, Shahbaz S, Sligl W, et al. Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection. mBio. 2021. https://doiorg.publicaciones.saludcastillayleon.es/10.1128/mBio.00384-21.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Elahi S. Hematopoietic responses to SARS-CoV-2 infection. Cell Mol Life Sci. 2022. https://doiorg.publicaciones.saludcastillayleon.es/10.1007/s00018-022-04220-6.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Shahbaz S, Dunsmore G, Koleva P, Xu L, Houston S, Elahi S. Galectin-9 and VISTA expression define terminally exhausted T cells in HIV-1 infection. J Immunol. 2020;204(9):2474–91.

    CAS  PubMed  Google Scholar 

  9. Shahbaz S, Jovel J, Elahi S. Differential transcriptional and functional properties of regulatory T cells in HIV-infected individuals on antiretroviral therapy and long-term non-progressors. Clin Transl Immunol. 2021;10(5):e1289.

    CAS  Google Scholar 

  10. Shahbaz S, Okoye I, Blevins G, Elahi S. Elevated ATP via enhanced miRNA-30b, 30c, and 30e downregulates the expression of CD73 in CD8+ T cells of HIV-infected individuals. PLoS Pathog. 2022;18(3):e1010378.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Dunsmore G, Rosero EP, Shahbaz S, Santer DM, Jovel J, Lacy P, et al. Neutrophils promote T-cell activation through the regulated release of CD44-bound Galectin-9 from the cell surface during HIV infection. PLoS Biol. 2021;19(8):e3001387.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Elahi S, Weiss RH, Merani S. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS. 2016;30(2):171–83.

    CAS  PubMed  Google Scholar 

  13. Brown LB, Spinelli MA, Gandhi M. The interplay between HIV and COVID-19: summary of the data and responses to date. Curr Opin HIV AIDS. 2021;16(1):63–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Pujari S, Gaikwad S, Chitalikar A, Dabhade D, Joshi K, Bele V. Coronavirus disease 19 among people living with HIV in Western India: an observational cohort study. Aids Res Hum Retrov. 2021;37(8):620–3.

    CAS  Google Scholar 

  15. Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases SA. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2021;73(7):e2005.

    Google Scholar 

  16. Ceballos ME, Ross P, Lasso M, Dominguez I, Puente M, Valenzuela P, et al. Clinical characteristics and outcomes of people living with HIV hospitalized with COVID-19: a nationwide experience. Int J STD AIDS. 2021;32(5):435–43.

    CAS  PubMed  Google Scholar 

  17. Peng XR, Ouyang J, Isnard S, Lin J, Fombuena B, Zhu B, et al. Sharing CD4+T cell loss: when COVID-19 and HIV collide on immune system. Front Immunol. 2020. https://doiorg.publicaciones.saludcastillayleon.es/10.3389/fimmu.2020.596631.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hoffmann C, Casado JL, Harter G, Vizcarra P, Moreno A, Cattaneo D, et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. Hiv Med. 2021;22(5):372–8.

    CAS  PubMed  Google Scholar 

  19. Bertagnolio S TS, Silva R, Ford N, Baggaley R, Vitoria M, Jassat W, Doherty M, Diaz J. Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO Global Clinical Platform. WHO Global Clinical Platform. https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1. Accessed 15 July 2021.

  20. Alrubayyi A, Gea-Mallorqui E, Touizer E, Hameiri-Bowen D, Kopycinski J, Charlton B, et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nat Commun. 2021;12(1):5839.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Shahbaz S, Xu L, Sligl W, Osman M, Bozorgmehr N, Mashhouri S, et al. The quality of SARS-CoV-2-Specific T cell functions differs in patients with mild/moderate versus severe disease, and T cells expressing coinhibitory receptors are highly activated. J Immunol. 2021;207(4):1099–111.

    CAS  PubMed  Google Scholar 

  22. Liu YB, Xiao YL, Wu SJ, Marley G, Ming FZ, Wang XY, et al. People living with HIV easily lose their immune response to SARS-CoV-2: result from a cohort of COVID-19 cases in Wuhan, China. Bmc Infect Dis. 2021. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12879-021-06723-2.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Elahi S, Dinges WL, Lejarcegui N, Laing KJ, Collier AC, Koelle DM, et al. Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med. 2011;17(8):989–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, et al. Lytic granule loading of CD8(+) T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008;29(6):1009–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Okoye IS, Houghton M, Tyrrell L, Barakat K, Elahi S. Coinhibitory receptor expression and immune checkpoint blockade: maintaining a balance in CD8(+) T cell responses to chronic viral infections and cancer. Front Immunol. 2017;8:1215.

    PubMed  PubMed Central  Google Scholar 

  27. Elahi S, Horton H. Association of HLA-alleles with the immune regulation of chronic viral infections. Int J Biochem Cell Biol. 2012;44(8):1361–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Okoye IS, Xu L, Walker J, Elahi S. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade. Cancer Immunol Immunother. 2020;69(8):1423–36.

    CAS  PubMed  Google Scholar 

  29. George VK, Pallikkuth S, Parmigiani A, Alcaide M, Fischl M, Arheart KL, et al. HIV infection Worsens age-associated defects in antibody responses to influenza vaccine. J Infect Dis. 2015;211(12):1959–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Motamedi M, Shahbaz S, Fu L, Dunsmore G, Xu L, Harrington R, et al. Galectin-9 expression defines a subpopulation of NK cells with impaired cytotoxic effector molecules but enhanced IFN-gamma production, dichotomous to TIGIT, in HIV-1 infection. Immunohorizons. 2019;3(11):531–46.

    CAS  PubMed  Google Scholar 

  31. Bozorgmehr N, Okoye I, Oyegbami O, Xu L, Fontaine A, Cox-Kennett N, et al. Expanded antigen-experienced CD160(+)CD8(+)effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia. J Immunother Cancer. 2021;9(4):e002189.

    PubMed  PubMed Central  Google Scholar 

  32. Motamedi M, Xu L, Elahi S. Correlation of transferrin receptor (CD71) with Ki67 expression on stimulated human and mouse T cells: the kinetics of expression of T cell activation markers. J Immunol Methods. 2016;437:43–52.

    CAS  PubMed  Google Scholar 

  33. Elahi S, Mashhouri S. Immunological consequences of extramedullary erythropoiesis: immunoregulatory functions of CD71(+) erythroid cells. Haematologica. 2020;105(6):1478–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Shahbaz S, Xu L, Osman M, Sligl W, Shields J, Joyce M, et al. Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2. Stem Cell Reports. 2021;16(5):1165–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Saito S, Shahbaz S, Sligl W, Osman M, Tyrrell DL, Elahi S. Differential impact of SARS-CoV-2 isolates, namely, the Wuhan strain, delta, and omicron variants on erythropoiesis. Microbiol Spectr. 2022. https://doiorg.publicaciones.saludcastillayleon.es/10.1128/spectrum.01730-22.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Bozorgmehr N, Okoye I, Mashhouri S, Lu J, Koleva P, Walker J, et al. CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors. J Immunother Cancer. 2023;11(5):e006595.

    PubMed  PubMed Central  Google Scholar 

  37. Shaath H, Vishnubalaji R, Elkord E, Alajez NM. Single-cell transcriptome analysis highlights a role for neutrophils and inflammatory macrophages in the pathogenesis of severe COVID-19. Cells-Basel. 2020;9(11):2374.

    CAS  Google Scholar 

  38. Okoye I, Xu L, Motamedi M, Parashar P, Walker JW, Elahi S. Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors. J Immunother Cancer. 2020;8(2):e001849.

    PubMed  PubMed Central  Google Scholar 

  39. Nkosi T, Chasara C, Papadopoulos AO, Nguni TL, Karim F, Moosa MS, et al. Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. Elife. 2022. https://doiorg.publicaciones.saludcastillayleon.es/10.7554/eLife.78374.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. De Biasi S, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. 2020. https://doiorg.publicaciones.saludcastillayleon.es/10.1038/s41467-020-17292-4.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory receptors beyond T cell exhaustion. Front Immunol. 2015;6:310.

    PubMed  PubMed Central  Google Scholar 

  43. Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in Immunity and Diseases. Curr Top Microbiol Immunol. 2017;410:75–97.

    CAS  PubMed  Google Scholar 

  44. Cossarizza A. T-cell repertoire and HIV infection: facts and perspectives. AIDS. 1997;11(9):1075–88.

    CAS  PubMed  Google Scholar 

  45. Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020. https://doiorg.publicaciones.saludcastillayleon.es/10.1172/jci.insight.137799.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B. Non-classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematous. Sci Rep. 2015;5:13886.

    PubMed  PubMed Central  Google Scholar 

  47. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020;95(6):E131–4.

    CAS  PubMed  Google Scholar 

  48. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43.

    CAS  PubMed  Google Scholar 

  49. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan. China Jama. 2020;323(11):1061–9.

    CAS  PubMed  Google Scholar 

  50. Elahi S. Neglected cells: immunomodulatory roles of CD71(+) erythroid cells. Trends Immunol. 2019;40(3):181–5.

    CAS  PubMed  Google Scholar 

  51. Namdar A, Dunsmore G, Shahbaz S, Koleva P, Xu L, Jovel J, et al. CD71(+) Erythroid cells exacerbate HIV-1 susceptibility, mediate trans-infection, and harbor infective viral particles. MBio. 2019. https://doiorg.publicaciones.saludcastillayleon.es/10.1128/mBio.02767-19.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Lee KW, Yap SF, Ngeow YF, Lye MS. COVID-19 in people living with HIV: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(7):3554.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clin Infect Dis. 2021;73(7):E1964–72.

    CAS  PubMed  Google Scholar 

  54. Tesoriero JM, Swain CAE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. Jama Netw Open. 2021;4(2):e2037069.

    PubMed  PubMed Central  Google Scholar 

  55. Mashhouri S, Koleva P, Huynh M, Okoye I, Shahbaz S, Elahi S. Sex matters: physiological abundance of immuno-regulatory CD71+ Erythroid cells impair immunity in females. Front Immunol. 2021;12:705197.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Lambarey H, Blumenthal MJ, Chetram A, Joyimbana W, Jennings L, Tincho MB, et al. SARS-CoV-2 infection is associated with uncontrolled HIV viral load in non-hospitalized HIV-infected patients from Gugulethu, South Africa. Viruses. 2022;14(6):1222.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the study participants for their contribution to the study. We also than the flow cytometry core at the University of Alberta.

Funding

This study was supported by the Canadian Institutes of Health Research (CIHR #453061 to SE).

Author information

Authors and Affiliations

  1. School of Dentistry, Division of Foundational Sciences, University of Alberta, Edmonton, AB, T6G 2E1, Canada

    Shima Shahbaz & Shokrollah Elahi

  2. Department of Critical Care Medicine, University of Alberta, Edmonton, AB, T6G 2E1, Canada

    Wendy Sligl

  3. Department of Medicine, Division of Infectious Diseases, University of Alberta, Edmonton, AB, T6G 2E1, Canada

    Wendy Sligl

  4. Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, AB, T6G 2E1, Canada

    Mohammed Osman

  5. Department of Oncology, University of Alberta, Edmonton, AB, T6G 2E1, Canada

    Shokrollah Elahi

  6. Li Ka Shing Institute of Virology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, T6G 2E1, Canada

    Shokrollah Elahi

Authors
  1. Shima Shahbaz
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Wendy Sligl
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Mohammed Osman
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Shokrollah Elahi
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

SS performed the research and drafted the manuscript. WS and MO recruited patients and collected clinical data. SE conceptualized and supervised the study, secured resources, designed contents and wrote the manuscript.

Corresponding author

Correspondence to Shokrollah Elahi.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Human Research Ethics Board (HREB) at the University of Alberta (Pro00099502). Waiver of consent was obtained by the HREB for those patients admitted to the ICU.

Consent for publication

All authors have read and approved the manuscript for publication.

Competing interests

The authors declare no potential conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shahbaz, S., Sligl, W., Osman, M. et al. Immunological responses in SARS-CoV-2 and HIV co-infection versus SARS-CoV-2 mono-infection: case report of the interplay between SARS-CoV-2 and HIV. Allergy Asthma Clin Immunol 19, 91 (2023). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13223-023-00846-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13223-023-00846-8

Keywords

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us